Status:
COMPLETED
An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care
Lead Sponsor:
Bayer
Conditions:
Metastatic Hormone-sensitive Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
This is an observational study in which only observations from routine clinical practices will be made. Participants will not receive any advice on treatment or any changes to healthcare as a part of ...
Eligibility Criteria
Inclusion
- Patients diagnosed with mHSPC
- Patients treated with darolutamide (Nubeqa, BAY1841788) in combination with ADT and docetaxel according to local reimbursement
- Initiation of treatment with darolutamide (Nubeqa, BAY1841788) in this indication between the index date (should be before 15MAR2024) and start of data collection.
Exclusion
- Participation in an investigational program with interventions outside of routine clinical practice
- Contraindications according to the local reimbursement
Key Trial Info
Start Date :
July 15 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 15 2024
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT06498921
Start Date
July 15 2024
End Date
September 15 2024
Last Update
October 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many locations
Multiple Locations, Belgium